Testosterone replacement therapy (TRT) can contribute to heart palpitations, and the mechanism is not simply “feeling jittery.” Testosterone directly alters the electrical behavior of heart muscle cells, and the largest randomized trial of TRT to date found a higher rate of atrial fibrillation in men receiving testosterone compared to placebo. Whether palpitations become a real problem for any individual depends on dose, baseline heart health, and how closely testosterone levels are monitored once treatment begins.
How Testosterone Changes the Heart’s Electrical Activity
Heart rhythm depends on the precise timing of electrical signals that tell each chamber when to contract. Those signals are generated by the flow of charged particles (mainly potassium, calcium, and sodium) through channels in heart muscle cells. Testosterone acts directly on two of those channels: it boosts potassium currents that speed up the cell’s return to resting state and suppresses calcium currents that normally slow that process down. The net result is a shorter “action potential duration,” which is the amount of time each cell spends in its electrically active state before resetting. In lab studies, testosterone shortened this duration at concentrations well within the normal male physiological range.1PubMed. Nontranscriptional regulation of cardiac repolarization currents by testosterone
A shorter action potential duration in the ventricles (the heart’s main pumping chambers) is generally considered protective against one type of dangerous arrhythmia. That is why men tend to have a shorter QT interval on an electrocardiogram than women, and why testosterone therapy shortens the QT interval in men with low testosterone.2PubMed. Effects of testosterone on ventricular repolarization in hypogonadic men But in the atria, the upper chambers that coordinate filling, a shorter action potential duration has the opposite effect: it makes the tissue more vulnerable to chaotic re-entry circuits, the hallmark of atrial fibrillation. A 2025 review put it plainly: estrogen lengthens the action potential in ways that protect the atria, while testosterone shortens it in ways that promote atrial fibrillation.3PubMed Central. Effect of estrogen and testosterone on cardiac electrophysiology and atrial fibrillation
This distinction matters because the palpitations most people notice during TRT are not the dangerous ventricular arrhythmias that cause sudden cardiac death. They are atrial events: premature beats, runs of rapid heartbeat, or full-blown atrial fibrillation. The electrical shortcut testosterone creates in atrial cells is one plausible reason why.
What the TRAVERSE Trial Showed
For years, TRT’s cardiac safety was debated using observational data that could never fully separate cause from effect. The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, changed that. It randomized over 5,200 men aged 45 to 80 who had low testosterone and either established cardiovascular disease or multiple risk factors. Half received testosterone gel, half received placebo, and they were followed for a median of roughly 33 months. The primary finding made headlines: TRT did not significantly increase the combined rate of heart attack, stroke, or cardiovascular death compared to placebo. But a secondary finding was less reassuring: a higher incidence of atrial fibrillation was observed in the testosterone group.4New England Journal of Medicine. Cardiovascular Safety of Testosterone-Replacement Therapy
The atrial fibrillation signal was not large enough to meet the threshold for a prespecified safety endpoint, so researchers and clinicians have debated how seriously to take it. An Australian randomized trial of testosterone in older men reported a similar pattern: eight arrhythmia events in the testosterone group compared to three in the placebo group, though total major cardiovascular events were similar between groups.5The Lancet Diabetes & Endocrinology. Testosterone for prevention of type 2 diabetes mellitus Neither trial was powered specifically to detect an arrhythmia difference, meaning they enrolled enough men to answer the bigger question (heart attacks and strokes) but not necessarily enough to confirm a smaller signal like atrial fibrillation with statistical certainty.
A separate analysis using insurance claims data from over 76,000 men found that TRT was not associated with a statistically significant increase in new-onset atrial fibrillation overall, though the point estimate still suggested a possible modest increase.6PubMed. Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury The inconsistency across studies is frustrating but not surprising: atrial fibrillation is a relatively uncommon event even in at-risk populations, and detecting a modest bump in risk requires very large sample sizes or long follow-up.
The Goldilocks Problem With Testosterone Levels
One of the more nuanced findings in this area is that both too-low and too-high testosterone levels appear to be linked to heart rhythm problems, though through different mechanisms. In men with active inflammatory illnesses, testosterone drops sharply, and that drop is associated with prolongation of the QT interval, a change that can set the stage for a specific dangerous rhythm called torsades de pointes.7PubMed Central. Transient Hypogonadism Is Associated With Heart Rate-Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men In other words, very low testosterone carries its own electrical risk.
At the other end, healthy older men whose endogenous testosterone naturally sits in the top fifth of the distribution face roughly double the risk of developing atrial fibrillation compared to men in the middle range. An analysis of over 7,000 men from the ASPREE trial found that those in the highest testosterone quintiles had about 18 to 19 new atrial fibrillation cases per 1,000 person-years, compared to notably fewer in the middle group.8eClinicalMedicine. Endogenous testosterone and risk of atrial fibrillation in healthy older men: a post-hoc analysis of the ASPREE randomized controlled trial
This U-shaped or J-shaped risk curve helps explain a counterintuitive finding from a large Veterans Affairs database study. Among men prescribed TRT, those whose testosterone levels actually normalized had a lower risk of atrial fibrillation compared to men whose levels remained low or were not adequately monitored. The group that achieved normal levels had about a 10 to 21 percent lower hazard of atrial fibrillation than the groups that did not normalize.9PubMed Central. Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation The practical takeaway is that careless dosing that pushes testosterone above the normal range, or inconsistent dosing that fails to bring levels into range, may carry more rhythm risk than carefully titrated therapy.
Structural Changes in the Heart
Beyond its immediate electrical effects, testosterone can physically remodel heart tissue over time. Animal studies using supraphysiological doses have shown that testosterone promotes thickening of heart muscle cells (hypertrophy) and the deposition of collagen fibers between those cells and the capillaries that feed them. This combination of a thicker wall and stiffer, fibrotic tissue creates a physical substrate for arrhythmias: electrical signals have to navigate around patches of scar-like tissue, making short-circuits and re-entry loops more likely.10PubMed Central. Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells – an ultrastructural and immunohistochemical study
In aged rabbits treated with testosterone, researchers observed a longer corrected QT interval, greater left ventricular mass, and reduced pumping efficiency in both the left atrium and left ventricle. The testosterone-treated animals also showed heightened activity in the part of the nervous system that accelerates heart rate, and their pulmonary vein tissue was more prone to generating abnormal electrical activity, exactly the kind that initiates atrial fibrillation in humans.11PubMed. Testosterone replacement increases aged pulmonary vein and left atrium arrhythmogenesis with enhanced adrenergic activity
These structural changes are dose-dependent and develop over time, which is why short-term trials may underestimate the long-term arrhythmia risk of TRT. A man who tolerates the first six months of therapy without palpitations is not necessarily in the clear if his dosing creeps upward or if cumulative remodeling gradually alters his atrial tissue.
Who Faces the Highest Risk
The TRAVERSE trial enrolled men who were already at elevated cardiovascular risk: most had established heart disease, diabetes, or both. A review published in the Journal of the Endocrine Society noted that whether the atrial fibrillation signal seen in TRAVERSE generalizes to younger or lower-risk men remains unclear. The available evidence suggests the risk is conditional on the baseline state of the atria; men who already have some degree of atrial enlargement, fibrosis, or elevated filling pressures are more likely to tip into fibrillation when testosterone shortens their atrial action potentials further.12Journal of the Endocrine Society. Association of testosterone and testosterone replacement therapy with atrial fibrillation: an updated review
This makes age a significant factor. Atrial fibrosis accumulates naturally with age, and most men starting TRT for age-related testosterone decline are in their 50s, 60s, or older. They may feel fine and have no history of arrhythmia, yet their atria may already have enough structural change to serve as kindling. The introduction of testosterone therapy could be the spark. Younger men starting TRT for clearly diagnosed pituitary or testicular conditions likely have healthier atrial tissue and face a meaningfully lower absolute risk, though the direct evidence for this reassurance is limited.
Other factors that raise the bar for concern include untreated obstructive sleep apnea (which is both worsened by TRT in some men and independently a major driver of atrial fibrillation), heavy alcohol use, and uncontrolled high blood pressure. If you already have one or more of these and are considering TRT, a baseline electrocardiogram and a conversation about arrhythmia monitoring are worth having before starting.
Palpitations That Are Not Atrial Fibrillation
Not every fluttery heartbeat on TRT means atrial fibrillation. Some of the palpitations men report are more mundane: premature atrial contractions or premature ventricular contractions, which are single extra beats that feel like a “skipped beat” or a brief thud in the chest. These are extremely common in the general population and usually harmless, though they feel alarming. Testosterone’s stimulation of the sympathetic nervous system, the fight-or-flight branch, may increase the frequency of these benign extra beats, especially in the first weeks of therapy when hormone levels are fluctuating.11PubMed. Testosterone replacement increases aged pulmonary vein and left atrium arrhythmogenesis with enhanced adrenergic activity
Fluid retention is another underappreciated contributor. TRT promotes sodium and water retention, which increases blood volume. A temporarily expanded blood volume makes the heart work harder with each beat, and the stretch on atrial walls can itself trigger ectopic beats. This effect tends to be most pronounced in the first few months and may settle as the body adjusts, but in men with borderline heart function, even modest fluid shifts can provoke symptoms.
Anxiety and heightened body awareness also play a role. Men starting testosterone often experience increased energy, improved mood, and sometimes heightened arousal, all of which involve sympathetic nervous system activation. Becoming more attuned to one’s body can make normal cardiac sensations, which were always there but went unnoticed, suddenly feel new and worrying. Distinguishing these benign palpitations from clinically meaningful arrhythmias usually requires monitoring: a 24- or 48-hour Holter monitor or a wearable patch that captures heart rhythm over days.
When Palpitations on TRT Escalate
A case presentation at the American College of Cardiology described a man who developed palpitations on testosterone therapy, initially evaluated with echocardiography, a Holter monitor, and a treadmill stress test, all of which came back unremarkable. A year later he presented with shortness of breath and palpitations severe enough to keep him from working. He was found to have atrial fibrillation with an elevated troponin (a marker of heart muscle injury), and echocardiography now showed a severely reduced ejection fraction of 19 percent, meaning his heart was pumping less than a fifth of its blood volume with each beat. His coronary arteries were normal on catheterization, pointing toward a non-ischemic cardiomyopathy.13JACC. PALPITATIONS ON TESTOSTERONE
This case is alarming but worth putting in context: the patient had hereditary hemochromatosis (iron overload), which independently damages heart muscle. The testosterone therapy was likely not the sole cause but may have accelerated rhythm deterioration in an already vulnerable heart. The case illustrates a broader principle: palpitations on TRT that are worsening, accompanied by exercise intolerance, or associated with near-fainting need urgent evaluation, not reassurance.
The QT Interval Paradox
If you search online for testosterone and heart rhythm, you will encounter seemingly contradictory information. Some sources say testosterone is protective because it shortens the QT interval, which reduces the risk of a particular ventricular arrhythmia. Others say testosterone promotes atrial fibrillation. Both statements are true, and they are not contradictory once you understand that the heart has different chambers with different electrical vulnerabilities.
A systematic review found a clear negative linear relationship between testosterone concentration and QT interval duration: higher testosterone, shorter QT.14PubMed. The Impact of Testosterone on the QT Interval: A Systematic Review In hypogonadal men, the difference in QT duration between the highest and lowest testosterone states was about 14 milliseconds, which is clinically meaningful.2PubMed. Effects of testosterone on ventricular repolarization in hypogonadic men For men who take medications that prolong the QT interval (certain antibiotics, antipsychotics, or anti-nausea drugs), testosterone’s QT-shortening effect could theoretically be protective. But that same electrical shortening, when it occurs in atrial tissue, tips the balance toward fibrillation. The heart does not let you pick and choose which chambers benefit.
Stimulants and Other Compounding Factors
Men on TRT do not exist in a pharmacological vacuum. Many also use caffeine in high doses, pre-workout supplements containing stimulants, or prescription medications for ADHD. A position statement from the European Association of Preventive Cardiology noted that amphetamine-type stimulants increase heart rate, blood pressure, and catecholamine release, all of which promote cardiac arrhythmias through overstimulation of the autonomic nervous system.15Oxford Academic. Cardiovascular effects of doping substances, commonly prescribed medications and ergogenic aids in relation to sports Layering these on top of testosterone’s own sympathetic activation and atrial electrical changes creates a higher-risk combination than either alone.
Anabolic steroid abuse, which involves testosterone doses many times above replacement levels, carries a far greater arrhythmia risk than medically supervised TRT. The structural remodeling, the degree of sympathetic activation, and the fluid retention are all amplified. Men who self-administer testosterone purchased from unregulated sources or who use additional anabolic compounds alongside prescribed TRT are in a different risk category entirely, and the clinical data from carefully dosed trials does not apply to them.
Practical Steps If You Experience Palpitations on TRT
If you notice a new pattern of skipped beats, racing heart, or a fluttering sensation after starting TRT, the response should be proportional to the symptoms. Occasional isolated skipped beats without dizziness or shortness of breath are worth mentioning at your next appointment but rarely require emergency evaluation. Sustained rapid heartbeat lasting more than a few minutes, especially if accompanied by lightheadedness, chest pressure, or difficulty breathing, warrants same-day medical attention. A smartwatch that records single-lead ECG tracings can be helpful for capturing what is happening during an episode, giving your doctor something concrete to review rather than relying on your description alone.
Your doctor should check your testosterone and hematocrit levels. Testosterone doses that push levels above the normal range, typically above roughly 1,000 ng/dL, increase hematocrit (the proportion of red blood cells in blood), which thickens the blood and strains the heart. A hematocrit above 54 percent is a common threshold for dose reduction or temporary suspension of therapy. Sleep apnea screening is also reasonable if it has not already been done, since TRT can worsen sleep-disordered breathing and the resulting overnight oxygen drops are themselves a potent trigger for atrial fibrillation.
For men whose palpitations turn out to be atrial fibrillation confirmed on monitoring, the decision about whether to continue TRT becomes a shared one between patient and physician. In some cases, reducing the dose to target the low-normal range, rather than the mid-to-high range, resolves the arrhythmia. In others, particularly men with structural heart disease or significant atrial enlargement, stopping TRT and exploring other management strategies for hypogonadism symptoms may be the safer path.
Hematocrit, Polycythemia, and the Circulation Connection
One of the most consistent side effects of TRT is erythrocytosis, an increase in red blood cell production. Testosterone stimulates the kidneys to produce more erythropoietin, which tells the bone marrow to make more red blood cells. This is why men on TRT need periodic blood counts. When hematocrit climbs too high, the blood becomes more viscous, and viscous blood is harder to pump. The heart compensates by working harder, which raises filling pressures and can stretch the atria. Atrial stretch is a well-known trigger for premature beats and atrial fibrillation.
This effect operates independently of testosterone’s direct electrical action on ion channels. Even if the electrical shortening of atrial action potentials were not an issue, the mechanical consequence of thicker blood and higher cardiac workload could be enough to provoke palpitations on its own. Injectable forms of testosterone, particularly long-acting esters that produce a spike in levels shortly after injection, tend to raise hematocrit more aggressively than gels or patches that deliver a steadier dose. Men who notice palpitations specifically in the days following an injection may be experiencing the combined impact of a testosterone surge and a transient hematocrit spike.